The efficacy of intranasal live attenuated influenza vaccine in children 2 through 17 years of age: A meta-analysis of 8 randomized controlled studies
Under a Creative Commons license
open access
Highlights
► LAIV efficacy in children 2–17 years was examined in 8 randomized controlled trials. ► Compared with placebo, LAIV efficacy was 78%–87% in years 1 and 2. ► Similar efficacy was observed against each type/subtype (A/H1N1, A/H3N2, and B). ► Compared with TIV recipients, LAIV recipients had 44%–50% less influenza illness. ► These data provide precise efficacy estimates for the approved pediatric age group.
Abbreviations
AOM
acute otitis media
LAIV
live attenuated influenza vaccine
RR
relative risk
TIV
trivalent inactivated influenza vaccine
Keywords
Influenza vaccine
Child
Live attenuated influenza vaccine
Trivalent inactivated influenza vaccine
Meta-analysis
Vaccine efficacy
Cited by (0)
Copyright © 2011 Elsevier Ltd.